Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 675-685

  Robson, Philip ^a,b  

^a Porton Down Science Park   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cannabidiol; cannabis; drug abuse; drug dependency; Sativex; tetrahydrocannabinol; withdrawal syndrome

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; NABILONE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATTENTION DISTURBANCE; CANNABIS ADDICTION; CANNABIS SMOKING; DECREASED APPETITE; DEPRESSION; DISORIENTATION; DRUG EFFECT; DRUG INTOXICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRUNKENNESS; EUPHORIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEUROPATHIC PAIN; ORAL SPRAY; ORGANIC PSYCHOSYNDROME; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; WITHDRAWAL SYNDROME;

CANNABINOIDS; CLINICAL TRIALS AS TOPIC; HUMANS; MARIJUANA ABUSE; MULTIPLE SCLEROSIS; PLANT EXTRACTS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE-RELATED DISORDERS; TETRAHYDROCANNABINOL;

EID: 80051985532     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.575778     Document Type: Review

References (48)

1. Christopher R. A cannabis chronology. Available from: Www.ukcia.org
2. Russo EB. History of cannabis and its preparations in saga, science and sobriquet. Chem Biodivers 2007;4:1614-48
3. Pertwee RG. Cannabinoid pharmacology: The first 66 years. Br J Pharmacol 2006;147:S163-71
4. Fleming MP, Clarke RC. Physical evidence for the antiquity of Cannabis sativa L. J Int Hemp Assoc 1998;5:80-92
5. World Drug Report 2008. Cannabis market. Available from: Www.undoc.org/ documents/wdr/WDR-2008/WDR2008-Cannabis-market.pdf
6. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7
7. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007;369:1047-53
8. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: A review of the literature. Am J Addict 2007;16:331-42
9. Vandrey RG, Budney AJ, Hughes JR, et al. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco and both substances. Drug Alc Depend 2008;92(1-3):48-54
10. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: How close are we? CNS Drugs 2009;23:543-53
11. Cooper ZD, Haney M. Actions of delta-9-tetrahydrocannabinol in cannabis:relation to use, abuse, dependence. Int Rev Psychiatry 2009;21:104-12
12. Mechoulam R. Marihuana chemistry. Science 1970;168:1159-63
13. Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13
14. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br Med J 2005;330:11
15. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psych 2004;161:1967-77
16. Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV). American Psychiatric Association 1994
17. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) 2007. Available from: Http://apps.who. int/classifications/apps/icd/icd10online/
18. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharm 2004;29:158-70
19. Diagnostic and Statistical Manual of Mental Disorders, proposed draft of the fifth Edition (DSM-5). American Psychiatric Association 2010. Available from: Www.dsm.org
20. Machado Rocha FC, Stefano SC, De Cassia Haiek R, et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis. Eur J Cancer Care 2008;17:431-43
21. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397-411
22. Available from: Http://who.int/ medicines/areas/quality-safety/ 4.2DronabinolCritReview.pdf
23. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 1998;30:187-96
24. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010;105:494-503
25. Montalban X, Sastre Garriga J, Vila C, Clissold SP. THC and CBD oromucosal spray (Sativex ) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurotherapeutics 2011; accepted for publication
26. Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today 2006;42:495-501
27. Zuardi AW. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30:271-80
28. Di Marzo V. The endocannabinoid system for the development of new drugs for spasticity. Drugs Future 2007;32:341-51
29. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39:421-9
30. Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234-46
31. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007;17:347-61
32. Nicholson AN, Turner C, Stone BM, Robson PJ. Effect of delta-9-THC and cannabidiol on nocturnal sleep and early morning behaviour in young adults. J Clin Psychopharmacol 2004;24:305-13
33. Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: Implications for possible symptomatic treatment in multiple sclerosis. Eur J Neurol 2008;15(Suppl 3):365
34. Guy GW, Robson P. A Phase-1, double blind, three-way crossover study to assess the pharmacokinetic profile of Cannabis Based Medicinal Extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy volunteers. J Cannabis Ther 2003;3:121-52
35. Sativex® integrated safety analysis, 2008. Data on file, GW Pharma
36. Sativex® integrated safety analysis, 2010. Data on file, GW Pharma
37. Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Goodman LS, Murad F, editors, The Pharmacological Basis of Therapeutics. 7th edition. Macmillan, New York; 1985
38. Tart CT. Marijuana intoxication: Common experiences. Nature 1970;226:701-4
39. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45
40. Wade D, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
41. Collin C, Davies P, Mutiboko IK, et al.; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
42. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9
43. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; doi: 10.1111/j.1468- 1331.2010.03328.x
44. Notcutt W, Davies P, Langford R, Ratcliffe S. Results of a randomised withdrawal study of subjects with spasticity due to multiple sclerosis who were receiving long-term Sativex®. Mult Scler 2009;15:S258
45. Schoedel K, Chen N, Guy GW, et al. Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. Eur Neuropsychopharmacol 2010;20(Suppl 3):S587
46. Levin FR, Kleber HD. Use of dronabinol for cannabis dependence: Two case reports and review. Am J Addict 2008;17:161-4
47. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007;4:4-16
48. Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacol 2009;56(Suppl 1):235-43